{"protocolSection": {"identificationModule": {"nctId": "NCT01001572", "orgStudyIdInfo": {"id": "CVAA489A2317"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension", "officialTitle": "A Multi-national, Multi-center, Double-blind, Randomized, Parallel Study Comparing the Efficacy and Safety of Valsartan/Amlodipine 160/5 mg to Valsartan 160 mg Alone in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Valsartan 160 mg Monotherapy"}, "statusModule": {"statusVerifiedDate": "2011-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-09"}, "primaryCompletionDateStruct": {"date": "2010-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-10-15", "studyFirstSubmitQcDate": "2009-10-23", "studyFirstPostDateStruct": {"date": "2009-10-26", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-04-22", "resultsFirstSubmitQcDate": "2011-05-18", "resultsFirstPostDateStruct": {"date": "2011-05-24", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-05-18", "lastUpdatePostDateStruct": {"date": "2011-05-24", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis Pharmaceuticals"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study assessed the efficacy and safety of the valsartan/amlodipine 160/5 mg single-pill combination in patients with uncomplicated essential hypertension not adequately controlled (MSDBP \u226590 mmHg and \\<110 mmHg) on valsartan 160 mg alone."}, "conditionsModule": {"conditions": ["Essential Hypertension"], "keywords": ["Blood pressure", "hypertension", "Exforge", "valsartan/amlodipine"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 932, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Valsartan 160 mg", "type": "ACTIVE_COMPARATOR", "description": "One capsule Valsartan 160 mg and 1 tablet placebo to Valsartan/Amlodipine taken orally once daily at approximately 9:00 AM for 8 weeks", "interventionNames": ["Drug: Valsartan 160 mg", "Drug: Placebo"]}, {"label": "Valsartan/amlodipine 160/5 mg", "type": "EXPERIMENTAL", "description": "One film-coated tablet Valsartan/amlodipine 160/5 mg and 1 capsule Placebo to Valsartan taken orally once daily at approximately 9:00 AM for 8 weeks", "interventionNames": ["Drug: Valsartan/amlodipine 160/5 mg", "Drug: Placebo"]}, {"label": "Single-Blind Run-In Valsartan 160 mg", "type": "OTHER", "description": "Single-Blind Run-In treatment with one capsule Valsartan 160 mg taken orally once daily at approximately 9:00 AM for 4 weeks.", "interventionNames": ["Drug: Valsartan 160 mg"]}], "interventions": [{"type": "DRUG", "name": "Valsartan/amlodipine 160/5 mg", "description": "Valsartan/amlodipine 160/5mg film coated tablets taken orally once daily.", "armGroupLabels": ["Valsartan/amlodipine 160/5 mg"], "otherNames": ["Exforge\u00ae 160/5mg"]}, {"type": "DRUG", "name": "Valsartan 160 mg", "description": "Valsartan 160 mg capsule taken orally once daily.", "armGroupLabels": ["Single-Blind Run-In Valsartan 160 mg", "Valsartan 160 mg"], "otherNames": ["Diovan\u00ae 160mg"]}, {"type": "DRUG", "name": "Placebo", "description": "1 capsule or tablet taken orally once daily", "armGroupLabels": ["Valsartan 160 mg", "Valsartan/amlodipine 160/5 mg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to Week 8 Endpoint", "description": "Three arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSDBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and center (pooled as appropriate) as factors and centered baseline MSDBP as a covariate.", "timeFrame": "Baseline and Week 8"}], "secondaryOutcomes": [{"measure": "Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to Week 8 Endpoint", "description": "Three arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSSBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and center (pooled as appropriate) as factors and centered baseline MSSBP as a covariate", "timeFrame": "Baseline and Week 8"}, {"measure": "Percentage of Participants With a Diastolic Blood Pressure Response at 8 Week Endpoint", "description": "The percentage of participants with a Diastolic Blood Pressure Response defined as the percentage of participants with a Mean Sitting Diastolic Blood Pressure (MSDBP) \\< 90 mmHg or a \\>= 10 mmHg reduction from baseline.", "timeFrame": "Baseline and Week 8"}, {"measure": "Percentage of Participants With Diastolic Blood Pressure Control at 8 Week Endpoint", "description": "The percentage of participants with Diastolic Blood Pressure Control defined as the percentage of participants with a Mean Sitting Diastolic Blood Pressure (MSDBP) \\< 90 mmHg.", "timeFrame": "Week 8"}, {"measure": "Percentage of Participants With Overall Blood Pressure Control at 8 Week Endpoint", "description": "The percentage of participants with Overall Blood Pressure Control defined as the percentage of participants with a Mean Sitting Systolic Blood Pressure (MSSBP)/Mean Sitting Diastolic Blood Pressure (MSDBP) \\< 140/90 mmHg.", "timeFrame": "Week 8"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must give written informed consent\n* Male or female ages 18 or older and less than 86 years\n* Diagnosed as having essential diastolic hypertension, as follows:\n\n  * Visit 2/Single-blind run-in entry, all participants MUST have a MSDBP \u2265 95 mmHg and \\< 100 mmHg\n  * At Visit 3/Core double-blind treatment period entry, all patients MUST have a MSDBP \\>=90 mmHg and \\<110 mmHg\n\nExclusion Criteria:\n\n* Severe hypertension\n* Evidence of secondary form of hypertension (coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's disease, pheochromocytoma or polycystic kidney disease )\n* Malignant hypertension\n* Administration of any agent indicated for the treatment of hypertension after Visit 1\n* Known moderate or malignant retinopathy.\n* Known or suspected contraindications, including history of allergy or hypersensitivity to Angiotensin II Receptor Blockers (ARBs), Calcium Channel Blockers (CCBs), or to drugs with similar chemical structures\n* History of hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack, myocardial infarction or all types of revascularization, angina pectoris of any type, including unstable angina\n* History of heart failure Grade II-IV according to New York Heart Association (NYHA) classification\n* Second of third degree heart block regardless of the use of a pacemaker, concomitant potentially life-threatening arrhythmia or symptomatic arrhythmia\n\nOther protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "85 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Sponsor GmbH", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Investigative site in Romainia"}, {"facility": "Novartis Investigative Site"}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "932 participants were entered into the single-blind valsartan 160 mg arm. 278 participants were discontinued from the single-blind arm. 654 participants were randomized into the double-blind treatment phase; 329 to the Valsartan/amlodipine arm and 325 to the valsartan alone arm.", "groups": [{"id": "FG000", "title": "Single-Blind Run -In Valsartan 160 mg", "description": "Single-Blind Run-In treatment with one capsule Valsartan 160 mg taken orally once daily at approximately 9:00 AM for 4 weeks."}, {"id": "FG001", "title": "Valsartan/Amlodipine 160/5 mg", "description": "One film-coated tablet Valsartan/amlodipine 160/5 mg and 1 capsule Placebo to Valsartan taken orally once daily at approximately 9:00 AM for 8 weeks."}, {"id": "FG002", "title": "Valsartan 160 mg", "description": "One capsule Valsartan 160 mg and 1 tablet placebo to Valsartan/Amlodipine taken orally once daily at approximately 9:00 AM for 8 weeks"}], "periods": [{"title": "Single-Blind Valsartan 160 mg", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "932"}, {"groupId": "FG001", "comment": "Participants did not enroll into this arm during single blind period.", "numSubjects": "0"}, {"groupId": "FG002", "comment": "Participants did not enroll into this arm during single blind period.", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "654"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "278"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "32"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Abnormal Test Procedure Result(s)", "reasons": [{"groupId": "FG000", "numSubjects": "96"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Abnormal Laboratory Value", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "82"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Condition no longer requires study drug", "reasons": [{"groupId": "FG000", "numSubjects": "45"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}, {"title": "Double-Blind Treatment Phase", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "This arm is only used for single blind period. So, no enrollment during double blind period.", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "329"}, {"groupId": "FG002", "numSubjects": "325"}]}, {"type": "Full Analysis Set (FAS)", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "comment": "One patient was excluded from full analysis set for having no post-baseline efficacy assessment.", "numSubjects": "328"}, {"groupId": "FG002", "comment": "Two patients were excluded from full analysis set for having no post-baseline efficacy assessment.", "numSubjects": "323"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "319"}, {"groupId": "FG002", "numSubjects": "306"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "19"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "13"}]}, {"type": "Abnormal test procedure result(s)", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Valsartan/Amlodipine 160/5 mg", "description": "One film-coated tablet Valsartan/amlodipine 160/5 mg and 1 capsule Placebo to Valsartan taken orally once daily at approximately 9:00 AM for 8 weeks."}, {"id": "BG001", "title": "Valsartan 160 mg", "description": "One capsule Valsartan 160 mg and 1 tablet placebo to Valsartan/Amlodipine taken orally once daily at approximately 9:00 AM for 8 weeks"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "328"}, {"groupId": "BG001", "value": "323"}, {"groupId": "BG002", "value": "651"}]}], "measures": [{"title": "Age Continuous", "description": "Baseline Measures were based on the Full Analysis Set that excludes 3 participants for having no post-baseline efficacy assessment.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "52.9", "spread": "9.47"}, {"groupId": "BG001", "value": "53.1", "spread": "9.41"}, {"groupId": "BG002", "value": "53.0", "spread": "9.43"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "141"}, {"groupId": "BG001", "value": "150"}, {"groupId": "BG002", "value": "291"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "187"}, {"groupId": "BG001", "value": "173"}, {"groupId": "BG002", "value": "360"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to Week 8 Endpoint", "description": "Three arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSDBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and center (pooled as appropriate) as factors and centered baseline MSDBP as a covariate.", "populationDescription": "Full Analysis Set includes all randomized participants who had both baseline and at least one post-baseline efficacy measurement. Last Observation Carried Forward.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 160/5 mg", "description": "One film-coated tablet Valsartan/amlodipine 160/5 mg and 1 capsule Placebo to Valsartan taken orally once daily at approximately 9:00 AM for 8 weeks."}, {"id": "OG001", "title": "Valsartan 160 mg", "description": "One capsule Valsartan 160 mg and 1 tablet placebo to Valsartan/Amlodipine taken orally once daily at approximately 9:00 AM for 8 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "328"}, {"groupId": "OG001", "value": "323"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.3", "spread": "0.39"}, {"groupId": "OG001", "value": "-6.6", "spread": "0.40"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to Week 8 Endpoint", "description": "Three arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSSBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and center (pooled as appropriate) as factors and centered baseline MSSBP as a covariate", "populationDescription": "Full Analysis Set includes all randomized participants who had both baseline and at least one post-baseline efficacy measurement. Last Observation Carried Forward.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 160/5 mg", "description": "One film-coated tablet Valsartan/amlodipine 160/5 mg and 1 capsule Placebo to Valsartan taken orally once daily at approximately 9:00 AM for 8 weeks."}, {"id": "OG001", "title": "Valsartan 160 mg", "description": "One capsule Valsartan 160 mg and 1 tablet placebo to Valsartan/Amlodipine taken orally once daily at approximately 9:00 AM for 8 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "328"}, {"groupId": "OG001", "value": "323"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-14.9", "spread": "0.61"}, {"groupId": "OG001", "value": "-7.0", "spread": "0.61"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With a Diastolic Blood Pressure Response at 8 Week Endpoint", "description": "The percentage of participants with a Diastolic Blood Pressure Response defined as the percentage of participants with a Mean Sitting Diastolic Blood Pressure (MSDBP) \\< 90 mmHg or a \\>= 10 mmHg reduction from baseline.", "populationDescription": "Full Analysis Set includes all randomized participants who had both baseline and at least one post-baseline efficacy measurement.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 160/5 mg", "description": "One film-coated tablet Valsartan/amlodipine 160/5 mg and 1 capsule Placebo to Valsartan taken orally once daily at approximately 9:00 AM for 8 weeks."}, {"id": "OG001", "title": "Valsartan 160 mg", "description": "One capsule Valsartan 160 mg and 1 tablet placebo to Valsartan/Amlodipine taken orally once daily at approximately 9:00 AM for 8 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "328"}, {"groupId": "OG001", "value": "323"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "70.1"}, {"groupId": "OG001", "value": "52.6"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Diastolic Blood Pressure Control at 8 Week Endpoint", "description": "The percentage of participants with Diastolic Blood Pressure Control defined as the percentage of participants with a Mean Sitting Diastolic Blood Pressure (MSDBP) \\< 90 mmHg.", "populationDescription": "Full Analysis Set includes all randomized participants who had both baseline and at least one post-baseline efficacy measurement.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Week 8", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 160/5 mg", "description": "One film-coated tablet Valsartan/amlodipine 160/5 mg and 1 capsule Placebo to Valsartan taken orally once daily at approximately 9:00 AM for 8 weeks."}, {"id": "OG001", "title": "Valsartan 160 mg", "description": "One capsule Valsartan 160 mg and 1 tablet placebo to Valsartan/Amlodipine taken orally once daily at approximately 9:00 AM for 8 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "328"}, {"groupId": "OG001", "value": "323"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "65.9"}, {"groupId": "OG001", "value": "50.8"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Overall Blood Pressure Control at 8 Week Endpoint", "description": "The percentage of participants with Overall Blood Pressure Control defined as the percentage of participants with a Mean Sitting Systolic Blood Pressure (MSSBP)/Mean Sitting Diastolic Blood Pressure (MSDBP) \\< 140/90 mmHg.", "populationDescription": "Full Analysis Set includes all randomized participants who had both baseline and at least one post-baseline efficacy measurement.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Week 8", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 160/5 mg", "description": "One film-coated tablet Valsartan/amlodipine 160/5 mg and 1 capsule Placebo to Valsartan taken orally once daily at approximately 9:00 AM for 8 weeks."}, {"id": "OG001", "title": "Valsartan 160 mg", "description": "One capsule Valsartan 160 mg and 1 tablet placebo to Valsartan/Amlodipine taken orally once daily at approximately 9:00 AM for 8 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "328"}, {"groupId": "OG001", "value": "323"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "61.3"}, {"groupId": "OG001", "value": "39.3"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Week 8", "description": "Safety population included all randomized patients who received at least one dose of double-blind trial medication.", "eventGroups": [{"id": "EG000", "title": "Valsartan/Amlodipine 160/5 mg", "description": "One film-coated tablet Valsartan/amlodipine 160/5 mg and 1 capsule Placebo to Valsartan taken orally once daily at approximately 9:00 AM for 8 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 329, "otherNumAffected": 0, "otherNumAtRisk": 329}, {"id": "EG001", "title": "Valsartan 160 mg", "description": "One capsule Valsartan 160 mg and 1 tablet placebo to Valsartan/Amlodipine taken orally once daily at approximately 9:00 AM for 8 weeks", "seriousNumAffected": 1, "seriousNumAtRisk": 325, "otherNumAffected": 0, "otherNumAtRisk": 325}], "seriousEvents": [{"term": "Uterine polyp", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 325}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862 778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000075222", "term": "Essential Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "asFound": "Essential Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000068756", "term": "Valsartan"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M319", "name": "Amlodipine, Valsartan Drug Combination", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}